Quantitation of acquired DNA mutations in pediatric patients with SCD receiving long-term hydroxyurea therapy at MTD
. | Baseline testing . | Follow-up testing . |
|---|---|---|
| No. patients | 26 | 26 |
| Age at testing, y | 7.8 ± 4.9 | 12.7 ± 5.1 |
| Duration of hydroxyurea therapy, mos | 3.9 ± 6.7 | 57.2 ± 9.5 |
| VDJ events per μg DNA | 1.36 ± 0.85 | 1.15 ± 0.41 |
. | Baseline testing . | Follow-up testing . |
|---|---|---|
| No. patients | 26 | 26 |
| Age at testing, y | 7.8 ± 4.9 | 12.7 ± 5.1 |
| Duration of hydroxyurea therapy, mos | 3.9 ± 6.7 | 57.2 ± 9.5 |
| VDJ events per μg DNA | 1.36 ± 0.85 | 1.15 ± 0.41 |
Each patient was tested at baseline and after an average of almost 5 years on hydroxyurea therapy. There was a small, but not statistically significant, decrease in the number of VDJ recombination events in association with hydroxyurea therapy at MTD. Baseline evaluations were performed as close to initiation of hydroxyurea as possible, though 9 patients had received hydroxyurea (median, 12 months) at the time of initial testing.